Does direct-to-consumer advertising of antidepressants lead to a net social benefit?

PharmacoEconomics

Volumn 26, Issue 7, 2008, Pages 557-566

  Jureidini, Jon ^a   Mintzes, Barbara ^b   Raven, Melissa ^c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Advertising; Antidepressants, therapeutic use; Cost benefit; Cost utility; Depression, treatment; Prescribing; Resource use

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CONSUMER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIAGNOSTIC ACCURACY; DIZZINESS; DRUG COST; DRUG MARKETING; DRUG WITHDRAWAL; ECONOMIC ASPECT; EXPOSURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEALTH CARE COST; HEALTH SURVEY; HOSPITALIZATION; HUMAN; LONG TERM CARE; MEDICAL CARE; NAUSEA; NOTE; PARESTHESIA; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; SEXUAL DYSFUNCTION; SOCIAL ASPECT; SUICIDE; VERTIGO;

ADVERTISING AS TOPIC; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DRUG COSTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 45749093330     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826070-00003     Document Type: Note

References (46)

1. Block A. Costs and benefits of direct-to-consumer advertising: the case of depression. Pharmacoeconomics 2007; 25 (6): 511-21
2. Iizuka T, Jin GZ. The effect of prescription drug advertising on doctor visits. J Econ Manag Strategy 2005; 14 (3): 701-27
3. Weissman JS, Blumenthal D, Silk AJ, et al. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff (Millwood) 2003 Jan-Jun; Suppl Web Exclusives: W3-82-95
4. Degner D, Grohman R, Kropp S, et al. Severe adverse drug reactions of antidepressants results of the German MultiCenter Drug Surveillance Program AMSP. Pharmacopsychiatry 2004; Suppl. 1: S39-45
5. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
6. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000. Summary: advance data from vital and health statistics. CDC June 5, 2002. Number 328: 1-32 [online]. Available from URL: http://www.cdc.gov/nchs/data/ad/ad328. pdf [Accessed 2008 Jun 4]
7. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289: 3095-105
8. Wakefield JC, Schmitz MF, First MB, et al. Extending the bereavement exclusion for major depression to other losses: evidence from the National Comorbidity Survey. Arch Gen Psychiatry 2007 Apr; 64 (4): 433-40
9. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 Feb; 5 (2): e45
10. Patten SB. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Popul Health Metr 2004 Nove 1; 2 (1): 9
11. The Henry J. Kaiser Family Foundation. Understanding the effects of direct-to-consumer prescription drug advertising. Menlo Park (CA): The Henry J. Kaiser Family Foundation, November 2001 [online]. Available from URL: http://www.kff.org/rxdrugs/upload/Understanding-the-Effects-of-Direct-to- Consumer-Prescription-Drug-Advertising-Report.pdf [Accessed 2008 Feb 18]
12. Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 2006; 3 (4): e198
13. United States Government Accountability Office. Prescription drugs: improvements needed in FDA's oversight of direct-to-consumer advertising. Washington, DC: United States Government Accountability Office, 2006 [online]. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?. IPaddress=162.140.64.183&filename=d0754.pdf&directory=/diska/wais/data/ gao [Accessed 2008 Mar 26]
14. National Institute for Health and Clinical Excellence. Depression: management of depression in primary and secondary care [clinical guideline 23]. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/ nicemedia/pdf/CG23quickrefguideamended.pdf [Accessed 2008 Mar 20]
15. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment on the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389-95
16. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer adverstised antidepressants: a randomized controlled trial. JAMA 2005 Apr 27; 293: 1995-2002
17. Aikin KJ. Direct-to-consumer advertising of prescription drugs: physician survey preliminary results. Rockville (MD): US Food and Drug Administration, 2003 [online]. Available from URL: http://www.fda.gov/cder/ddmac/ globalsummit2003 [Accessed 2008 Jun 1]
18. Frank RG, McGuire TG, Normand SL, et al. The value of mental health care at the system level: the case of treating depression. Health Aff (Millwood) 1999; 18: 71-88
19. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005; 3: 449-56
20. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-60
21. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depresison in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008; 178: 296-305
22. Goldberg D, Privett M, Ustun B, Simon G, Linden M. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Br J Gen Pract 1998 48: 1840-1844
23. Ronalds C, Creed F, Stone K, et al. Outcome of anxiety and depressive disorders in primary care. Br J Psychiatry 1997 Nov; 171: 427-33
24. Brugha TS, Bebbington PE, MacCarthy B, et al. Antidepressants may not assist recovery in practice: a naturalistic prospective survey. Acta Psychiatr Scand 1992 Jul; 86 (1): 5-11
25. Healy D, Alfred G. Antidepressant drug use and the risk of suicide. Int Rev Psychiatry 2005; 17: 163-72
26. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396-402
27. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911-32
28. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000 May 2; 132 (9): 743-56
29. Gartlehner G, Hansen RA, Kahwati L, et al. Drug class review on second generation antidepressants. Drug Effectiveness Review Project. Sept 2006 [online]. Available from URL: http://www.ohsu.edu/drugeffectiveness/reports/ final.cfm [Accessed 2008 Mar 20]
30. Lima MS, Moncrieff J. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev 2000; (4): CD001130
31. Montego AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001; (62 Suppl. 3): 10-21
32. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998 Jul 15; 44 (2): 77-87
33. Bogetto F, Bellino S, Revello RB, et al. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002; 16 (4): 273-83
34. Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006; 20 (2): 143-51
35. Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67 Suppl. 4: 27-30
36. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004 60: 57-61
37. Ruhé HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006 Dec; 67 (12): 1836-55
38. Rascati K, Godley P, Pham H. Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. J Manag Care Pharm 2001 Sep-Oct; 7 (5): 402-6
39. Iqbal SU, Prashker M. Pharmacoeconomic evaluation of antidepressants: a critical appraisal of methods. Pharmacoeconomics 2005; 23 (6): 595-606
40. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008 Jan; 165 (1): 42-50
41. Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom Med 1998; 60: 143-9
42. Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998 Jul; 55 (7): 645-51
43. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1999
44. McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry 2004 Mar; 49 (3 Suppl. 1): 10S-6S
45. Spijker J, de Graaf R, Bijl RV, et al. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002 Sep; 181: 208-13
46. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9 (2): 87-98